Personalised Medicine – Rheumatoid arthritis (RA)

Patients with RA are stratified according to biomarkers in the blood – rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) when they present to the clinic and blood is taken for analysis at baseline and subsequent visits at 3, 6 and 12 months. In addition, if patients switch therapy (a) to a different DMARD; (b) to a biologic medicine; (c) to a different biologic medicine blood, synovial fluid and synovial tissue is obtained when feasible.